menu

Media Center

epiXchange conference

23 May 2018, Brussels

The epiXchange conference 2018 was fully recorded. Here you can find the full live-stream as well as special cutouts: the opening & key-note speech, the project overviews, the five thematic sessions and the concluding remarks of epiXchange 2018. You can find the single talks of the speakers in the drop-down menu next to the relevant session. To discover the image gallery of epiXchange 2018 please follow the link below:

To the Image Gallery »



Conference Feature

epiXchange2018


180 Seconds Interviews

with epiXchange2018 Organisers

  • Helen Cross
    EpiCARE
  • Renzo Guerrini
    DESIRE
  • David Henshall
    EpimiRNA
  • Sergiusz Jóźwiak
    EPISTOP
  • Merab Kokaia
    EPITARGET
  • Janet Mifsud | Asla Pitkänen
    DESIRE | EPITARGET
  • Michele Simonato
    Epixchange

Opening Speech

David Henshall, EpimiRNA

  • Video

Project Overviews

Coordinators of Projects

  • DESIRE
    Renzo Guerrini
  • EpimiRNA
    David Henshall
  • EPIPGX
    Gianpiero Cavalleri
  • EPISTOP
    Sergiusz Jóźwiak
  • EPITARGET
    Merab Kokaia
  • Epixchange
    Michele Simonato
  • EpiCARE
    Helen Cross

Key Note Speech

Karim Berkouk, DG Research & Innovation at European Commission

  • Video Presentation

Translational Research in Biomarkers

Chairs: A. Pitkänen (University of Eastern Finland), M. Simonato (Università degli Studi di Ferrara)

  • Short overview
    A.Pitkänen (EPITARGET – University of Eastern Finland)
  • Epigenetic biomarkers in FCDs

    K. Kobow (DESIRE – Friedrich-Alexander-Universität Erlangen-Nürnberg)
  • MicroRNA as biomarkers of epilepsy and status epilepticus
    F. Rosenow (EpimiRNA – Goethe-Universität Frankfurt & Philipps-Universität Marburg)
  • Predictors of adverse reactions to AEDs

    G. Cavalleri (EpiPGX – Royal College of Surgeons in Ireland)
  • EEG changes as biomarker for emerging epilepsy in TSC
    L. Lagae (EPISTOP – Katholieke Universiteit Leuven)
  • HMGB1 as a predictive biomarker for preclinical and clinical studies

    A. Vezzani (EPITARGET – Mario Negri Institute)
  • Questions & Answers
    All Speakers

Due to confidentiality issues not publicly available.


Genetics of Epilepsy - Therapeutics Implications

Chairs: D. J. Kwiatkowski (Harvard University), R. Guerrini (Università degli Studi di Firenze)

  • Short overview
    R. Guerrini (DESIRE – Università degli Studi di Firenze)
  • Genetics of epileptogenic disorders: update and consequences on patients' therapeutic management
    R. Guerrini (DESIRE – Università degli Studi di Firenze)
  • The emerging role of genetics in the clinical care pathway

    R. Nabbout (EpiCARE - CHU Paris)
  • Genetic variation in microRNAs and their targets in epilepsy
    I. Lopes-Cendes (EpimiRNA – Universidade Estadual de Campinas)
  • Predictors of responses to AEDs

    H. Lerche (EpiPGX – Universität Tübingen)
  • Genetics and mosaicism in Tuberous Sclerosis Complex: preliminary analysis of association with seizure phenotype in EPISTOP
    D. Kwiatkowski (EPISTOP – Harvard University)
  • Functional epigenomic dissection of epilepsy in human brain biopsy tissue and corresponding mouse models
    A. Becker (EPITARGET – Universität Bonn)
  • Questions & Answers
    All Speakers

Due to confidentiality issues not publicly available.


Innovation Therapeutics & Translation

Chairs: F. Rosenow (Goethe-Universität Frankfurt & Philipps-Universität Marburg), M. Kokaia (Lunds Universitet)

  • Short overview
    M. Kokaia (EPITARGET - Lunds Universitet)
  • Innovative therapeutic strategies for epileptic encephalopathies
    F. Benfenati (DESIRE – Istituto Italiano Di Tecnologia)
  • Improving clinical trials in epilepsy: addressing the hurdles and filling the gaps
    E. Perucca (EpiCARE – ILAE/ Università degli Studi di Pavia)
  • MicroRNAs as targets for seizure control and disease-modification
    D. Henshall (EpimiRNA – Royal College of Surgeons in Ireland)
  • Preseizure vs postseizure treatment of epilepsy - pros and cons
    S. Jóźwiak (EPISTOP – Warszawski Uniwersytet Medyczny)
  • Evaluation of tolerability and antiepileptogenic efficacy of multitargeted drug combinations by a two-stage approach
    W. Löscher (EPITARGET – Stiftung Tierarztliche Hochschule Hannover)
  • Differential effect of neuropeptides on excitatory synaptic transmission in human epileptic hippocampus
    M. Ledri (Epixchange – Lunds Universitet)
  • Questions & Answers
    All Speakers

Understanding Co-Morbidities in the Epilepsies

Chairs: H. Cross (University College London), S. Jóźwiak (Warszawski Uniwersytet Medyczny)

  • Short overview
    S. Jóźwiak (EPISTOP – Warszawski Uniwersytet Medyczny)
  • Perspectives for investigating physiopathological mechanisms of co-morbidities in epilepsy
    A. Represa (DESIRE – INSERM)
  • Predictors of response and resistance and co-morbidities
    C. Leu (EpiPGX – University College London)
  • Autism in tuberous sclerosis: early developmental trajectories, potential biomarkers and treatment strategies
    P. Curatolo (EPISTOP – Policlinico Tor Vergata)
  • Systems genetic evidence for a convergence of epilepsy and its co-morbidies on shared molecular pathways
    M. Johnson (EPITARGET – Imperial College London)
  • Effects on seizures and epilepsy co-morbidities of encapsulated BDNF-producing cells
    C. Falcicchia (Epixchange – Università degli Studi di Ferrara)
  • Questions & Answers
    All Speakers

Biobanks and Databases - Basis for Translational Research

Chairs: S. Sisodiya (University College London), K. Kobow (Friedrich-Alexander-Universität Erlangen-Nürnberg)

  • Short overview
    K. Kobow (DESIRE – Friedrich-Alexander-Universität Erlangen-Nürnberg)
  • Success of the European Epilepsy Brain Bank
    I. Blümcke (DESIRE & EpiCARE – ILAE/ Friedrich-Alexander-Universität Erlangen-Nürnberg)
  • Multi-omic atlas of functional microRNA for epilepsy
    A. Ahonen-Bishopp(EpimiRNA – BCPlatforms)
  • Controlled  access resources for genetic and pharmacogenetics research for epilepsy
    R. Krause (EpiPGX – Université du Luxembourg)
  • Biobanking in Tuberous Sclerosis Complex : challenges and opportunities for  understanding epilepsy and cognitive and behavioural co-morbidities
    E. Aronica (EPISTOP – Universiteit van Amsterdam)
  • Database for powered preclinical multicenter trial
    A.Pitkänen (EPITARGET – University of Eastern Finland)
  • Questions & Answers
    All Speakers

Concluding Remarks

Janet Mifsud, DESIRE – University of Malta

  • Video Presentation